Hyloris Secures European, Turkish License for ArborMed's Rare Disease Drug

12:51 AM EST, 12/31/2025 (MT Newswires) -- Hyloris Pharmaceuticals (HYL.BR) said Tuesday it signed a licensing deal for South Korea-based ArborMed's investigational therapy for Wilson's disease, a rare metabolic condition, across Europe and Turkey. Under the deal, the specialty biopharma company will make an upfront payment of $2 million to obtain the rights to commercialize the drug candidate, as well as sublicense. ArborMed may receive a share of future profits for sublicense, or a combination of royalties and sales-based milestone payments if Hyloris directly commercializes the drug. The agreement also allows ArborMed to retain a contractual option to reacquire Hyloris' rights before phase 3 clinical development. If the option is exercised, Hyloris will be reimbursed the upfront license fee, while remaining entitled to ongoing payments.